{"id":261,"date":"2019-11-14T21:00:37","date_gmt":"2019-11-15T02:00:37","guid":{"rendered":"https:\/\/opentextbc.ca\/nursingpharmacology\/chapter\/5-13-leukotriene-receptor-antagonists\/"},"modified":"2023-08-15T13:08:40","modified_gmt":"2023-08-15T17:08:40","slug":"5-13-leukotriene-receptor-antagonists","status":"publish","type":"chapter","link":"https:\/\/opentextbc.ca\/nursingpharmacology\/chapter\/5-13-leukotriene-receptor-antagonists\/","title":{"raw":"5.13 Leukotriene Receptor Antagonists","rendered":"5.13 Leukotriene Receptor Antagonists"},"content":{"raw":"

Leukotriene Receptor Antagonists<\/h1>\r\nMontelukast is a leukotriene antagonist medication with a distinctly shaped tablet. See Figure 5.13<\/a>.[footnote]\"Singulair 10mg<\/a>\" by FedEx<\/a> is licenced under CC BY-NC-ND 2.0<\/a>[\/footnote]\r\n

Mechanism of Action<\/h2>\r\nMontelukast blocks leukotriene receptors and decreases inflammation.\r\n

Indications for Use<\/h2>\r\nMontelukast is used for the long-term control of asthma and for decreasing the frequency of asthma attacks.\u00a0 It is also indicated for exercise-induced bronchospasm and allergic rhinitis.\r\n

Nursing Considerations Across the Lifespan<\/h2>\r\nThe medication is safe for children 12 months and older. It is available in granule packets and chewable tablets, as well as regular tablets.\r\n

Adverse\/Side Effects<\/h2>\r\nMontelukast can cause headache, cough, nasal congestion, nausea, and hepatotoxicity.[footnote]Frandsen, G. & Pennington, S. (2018). Abrams\u2019 clinical drug: Rationales for nursing practice <\/em>(11th ed.). Wolters Kluwer.[\/footnote]<\/a>\r\n\r\n[caption id=\"attachment_260\" align=\"aligncenter\" width=\"433\"]\"Photo Figure 5.13 Montelukast Tablets[\/caption]\r\n

Client Teaching & Education<\/h2>\r\nClients should be instructed to take medications at the same time each day and at least two hours prior to exercise.\u00a0 They should not discontinue medications without notifying the healthcare provider.[footnote]uCentral from Unbound Medicine. https:\/\/www.unboundmedicine.com\/ucentral<\/a>[\/footnote]\r\n

Montelukast Medication Card<\/h1>\r\nNow let's take a closer look at the medication card on montelukast.[footnote]This work is a derivative of Pharmacology Notes: Nursing Implications for Clinical Practice<\/a> by Gloria Velarde<\/a> licensed under CC BY-NC-SA 4.0<\/a>.[\/footnote][footnote]Frandsen, G. & Pennington, S. (2018). Abrams\u2019 clinical drug: Rationales for nursing practice <\/em>(11th ed.). Wolters Kluwer.[\/footnote], [footnote]This work is a derivative of Daily Med<\/a> by U.S. National Library of Medicine<\/a> in the public domain<\/a>. [\/footnote][footnote]Adams, M., Holland, N., & Urban, C. (2020). Pharmacology for nurses: A pathophysiologic approach <\/em>(6th ed.).<\/em> pp. 622-63 & 626. Pearson.[\/footnote] Because information about medication is constantly changing, nurses should always consult evidence-based resources to review current recommendations before administering specific medication.\r\n
\r\n

Medication Card 5.13.1: Montelukast<\/h2>\r\n<\/header>\r\n
\r\n\r\nClass: <\/strong>Leukotriene Receptor Antagonists\r\n\r\nPrototypes: <\/strong>Montelukast (Singulair)\r\n\r\nMechanism: <\/strong>Montelukast blocks leukotriene receptors and decreases inflammation\r\n

Therapeutic Effects<\/h3>\r\n